Phosphorylated ACLY expression was significantly associated with stage, differentiation and prognosis in patients with lung adenocarcinoma (Migita et al, 2008), and high ACLY expression was associated with drug resistance, recurrence and poor prognosis in breast cancer (Chen et al, 2020). This evidence concerns the gene ACLY and breast carcinoma.